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Chapter 7: Patenting Bioprinting-Technologies in the US and 
Europe– The 5th Element in the 3rd Dimension 
 
Timo Minssen & Marc Mimler∗ 
 
“Me fifth element- supreme being. Me protect you”  
-LeeLoo in “The Fifth Element” (Columbia Pictures 1997)- 
  
 
Introduction∗∗ 
 
When entering the headquarters of the US Bioprinting company “Organovo” at 6275 Nancy 
Ridge Drive in San Diego, California,1  you might meet Bruce Willis. The famous actor stares 
at researchers from a machine in a sterile room, where several bioprinters carry labels with the 
names of characters from the 1997 sci-fi motion picture The Fifth Element.2 In the movie, 
which is set in the 23rd century, a robotic machine uses cells from a severed human hand to 
print and reanimate the “Fifth Element”.3 The creature turns out to be a highly enhanced and 
very capable “supreme being” named LeeLoo. 
Today’s science is still far from achieving anything resembling such sci-fi wonders, but 
scientists have made fascinating advances in developing sophisticated tools that enable us to 
better visualize and model such processes.4 Moreover, they have made promising advances in 
starting to address one of the major challenges: to make printed tissue behave like real tissue 
in a biological organism. In 2016, for example, Hyun-Wook Kangsee and his co-authors 
published their paper entitled “A 3D bioprinting system to produce human-scale tissue 
constructs with structural integrity” in Nature Biotech and announced: 
 
We present an integrated tissue–organ printer (ITOP) that can fabricate stable, human-scale tissue 
constructs of any shape. Mechanical stability is achieved by printing cell-laden hydrogels together 
with biodegradable polymers in integrated patterns and anchored on sacrificial hydrogels. The 
correct shape of the tissue construct is achieved by representing clinical imaging data as a computer 
model of the anatomical defect and translating the model into a program that controls the motions 
of the printer nozzles, which dispense cells to discrete locations.5 
 
While producing three-dimensional, vascularized cellular constructs of clinically 
relevant size, shape and structural integrity certainly remains a major challenge for tissue 
engineering, Hyun-Wook Kangsee and his colleagues succeeded in incorporating 
microchannels into tissue-constructs, which enhances the diffusion of nutrients to printed 
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2 Steven Leckart, How 3-D Printing Body Parts Will Revolutionize Medicine, Popular Science, available at: 
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5   Hyun-Wook, Kang et al., A 3D bioprinting system to produce human-scale tissue constructs with structural 
integrity , 34 Nature Biotechnology, 312–319 (2016). 
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cells.6 In addition to increasing the chances of cell survival in engineered tissues by this 
achievement, they further demonstrated the capabilities of their 3 D bioprinter to produce 
“mandible and calvarial bone, cartilage and skeletal muscle”.7 Moreover, they announced that 
the future development of their bioprinting research is being directed to “the production of 
tissues for human applications and to the building of more complex tissues and solid organs”.8 
Building upon such fascinating research results, today’s state-of-the art 3 D bioprinting 
companies, such as Organovo, aim at designing, creating and ultimately selling living human 
tissues that with increasing accuracy represent human biology and function, like native tissues 
and organs. Their vision and mission is to use 3 D bioprinting technologies in order to develop 
groundbreaking therapies and to bridge the gap between pre-clinical testing and clinical trials.9 
To achieve these ambitious goals, they team up with biopharmaceutical companies, hospitals 
and academics to design, build, and validate more predictive in vitro tissues for disease 
modelling and toxicology. This entails the opportunity to test drugs on functional human 
tissues before ever administering the drug to a living person or to create functional, three-
dimensional tissues that can be implanted or delivered into the human body to improve, repair 
or replace damaged or diseased tissues.10 
These enormous opportunities and the broader implications of bioprinting raise a wide 
variety of crucial legal issues. These may range from regulation of the science, its societal 
effects and wider ethical implications to questions regarding commercialization, innovation 
policy and governance of the technology. A broader analysis of all these important issues falls 
outside the limited scope of this paper. Rather, we will concentrate on selected 
commercialization aspects and in particular the question of what types of products and uses 
should be regarded as protectable subject matter under the relevant intellectual property right 
(IPR) frameworks. Considering that the availability of IPRs might have a great impact on 
where the greatest investments and scientific efforts in this technology will be made, this is a 
significant question. In addition to trade secrets, copyrights, trademarks and other IPR-related 
rights, patents will certainly play a major role in that respect and will thus be the primary 
focus of this paper.  
In the following, we examine what sorts of bioprinting inventions are being patented or 
would be protectable under European and US patent laws. Rather than focusing on the highly 
relevant questions that 3D printing poses for patent infringement doctrines and research 
exemptions11, this paper concentrates on the question of patentable subject matter and 
patentability. To this end, we start out by (1) briefly describing the relevant state of the art in 
bioprinting. This allows us to better describe and understand the current bioprinting patent 
landscape (2), and to examine how far any future inventions stemming from such technology 
would meet the most basic US and European patent requirements (3). A related question is, of 
course, whether some bioprinting technologies should be categorically excluded from 
                                                          
6 Ibid. 
7Ibid., 312. 
8Ibid.,312.  
9 See the homepage of Organovo, available at: http://organovo.com/about/about-organovo/ (accessed 18 
November 2016). 
10 Ibid. 
11 A good overview of US infringement issues relating to 3D printing is provided by Timothy R. Holbrook, and 
Lucas Osborn, Digital Patent Infringement in an Era of 3D Printing. 48 UC Davis Law Review, 1319-1385 
(2015). Regarding the situation in Australia and Europe, cf. Johnathon E Liddicoat, Jane L. Nielsen, & Dianne 
Nicol, Three Dimensions of Patent Infringement: Liability for Creation and Distribution of CAD Files, 
Australian Intellectual Property Journal (2016), available at SSRN: https://ssrn.com/abstract=2792601; Rosa 
Maria Ballardini, Marcus Norrgård, and Timo Minssen, Enforcing Patents in the Era of 3D Printing, 10(11), 
Journal of Intellectual Property Law and Practice, 850 (2015); Marc Mimler, 3D Printing, the Internet and Patent 
Law – A History repeating?, 62 (6) La Rivista di Diritto Industriale, 352 – 370 (2013). 
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patentability, i.e. even when meeting the most basic patent criteria, or whether they are barred 
from patenting because they are perceived to be immoral. We address this specific issue by 
discussing patent limitations and morality exclusions from patent law (4), which will allow us 
to complete the paper with some concluding remarks (5).  
 
 
1.  Bioprinting: A brief scientific preface 
 
Bioprinting is an emerging field of technology that is part of the wider field of tissue 
engineering and uses 3D printing technology.12 Bioprinting is used to fabricate three-
dimensional structures of biological materials, generally cells and biochemicals, through 
layer-by-layer precise positioning.13 The printing process is controlled by a computer 
according to a predetermined instruction, usually a computer-aided design (CAD) file of the 
respective tissues or object. The ultimate goal of the technology is to replicate functioning 
tissue and material, up to full organs which then can be transplanted into human beings.14 
In order to be able to print complex tissues and organs, a model of the object to be 
printed needs to be produced and which is able to instruct the 3D printer. This is a complex 
task as the objects that are aimed to be reproduced are complex and heterogeneous.15 In order 
to provide a printing template, medical imaging is used to create a virtual image of the 
construct by using computed tomography (CT) scans or magnetic resonance imaging.16 After 
these images are created, further processing leads to the creation of a CAD file which can be 
used to instruct the printer. Where an exact copy of the patient’s organ is not required or 
desirable, computer modelling can be applied to design the desired structure.17 
A further component of the bioprinting process is the “ink” the printer uses. Such 
“bioink” can, for instance, consist of autologous cells, i.e. cells that have been taken from a 
patient through biopsy.18 Bioink can also be made of cells from different individuals from the 
same species (allogenic cells) and also from cells from different species (xenogenic cells).19 
After isolation of the cells, these are then cultivated and multiplied in vitro.  
Aside from cells, bioink consists of a hydrogel pre-polymer-solution.20 Such hydrogels 
are crucial for the success of bioprinting and need to possess certain properties.21 It has to be 
borne in mind that 3D printing was originally developed for non-biological applications, such 
as rapid prototyping, which operate in conditions that are not suitable for use of biomaterials, 
                                                          
12 Jasper L. Tran, To Bioprint or not to Bioprint, 17 (1) N.C. J.L. & TECH., 123, 132 (2015), refers to bioprinting 
as “the stepchild of 3D Printing and synthetic biology”. 
13 Sean V Murphy & Anthony Atala, 3D bioprinting of tissues and organs, 32 (8) Nature Biotechnology, 773 
(2014). 
14 Chee Kai Chua and Wai Yee Yeong, Bioprinting : Principles and Applications, 53 World Scientific Publishing 
Company (2015); Mathew Varkey and Anthony Atala, Organ bioprinting: A closer look at ethics and policies, 5 
Wake Forest Journal of Law & Policy 275, 277 (2015). 
15 Dhakshinamoorthy Sundaramurthi, Sakander Raud and Charlotte A. E. Hauser, 3D bioprinting for 
regenerative medicine applications (2) International Journal of Bioprinting, 9, 21 (2016). 
16 Soumen Jana and Amir Lerman, Bioprinting a cardiac valve, 33 (8) Biotechnology Advances 1503-1521, 1505 
(2015); Murphy & Atala, supra n. 13, 775; Shuai Wang, Jia Min Lee & Wai Yee Yeong, Smart hydrogels for 3D 
bioprinting, 1 (1) International Journal of Bioprinting, 3, 4 (2015); Christian Mandrycky, Zongjie Wang, 
Keekyoung Kim and Deok-Ho Kim, 3D bioprinting for engineering complex tissues, 34 (4) Biotechnology 
Advances 422-434, 426 (2016). 
17 Murphy & Atala, supra n. 13, 775. 
18 Chua & Yeong, supra n. 14, 165. 
19 Ibid., 166. 
20 Mandrycky, Wang, Kim & Kim, supra n. 16, 427. 
21 Wang, Lee & Yeong, supra n. 16, 5. 
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such as heat and pressure during the printing process.22  These conditions may negatively 
affect the viability of cells.  
Hence, the materials used for bioink need to be capable of sustaining these conditions 
while being able to enhance cell viability during and after the printing process.23 The material 
should also be printable and capable of being deposited accurately. Additionally, the material 
would need to be biocompatible, i.e. able to provide a favourable environment for the cells.24 
After the printing process, the bioinks should be able to provide structural and mechanical 
support.25 Finally, the material uses should be biodegradable.26 This means that the 
scaffolding function initially provided by the hydrogel should be taken over by growing 
cells.27 Commonly, materials such as collagen, gelatine, fibrin, and other natural polymers are 
used for bioink.28 But synthetic polymers are also applied due to their particular 
characteristics, i.e. “their biocompatibility, strong mechanical properties [and] degradation 
profile”.29  
Currently in use are three common bioprinting techniques30: inkjet, laser assisted and 
extrusion bioprinting – all of which have strengths and shortcomings.31 Inkjet printing was the 
first method applied in this context. It resembles two-dimensional inkjet printing32 and is a 
widely used method of bioprinting.33 The printer head generates droplets by thermal or 
acoustic force34 to eject the bioink35 and prints the bioink according to a prescribed way.36 
This technology, however, has its drawbacks as it is not able to print bioink of high 
viscosity.37 The lower level of cell concentrations that are used make it difficult to create cell 
densities which are relevant.38 The advantages of this technology, on the other side, are its low 
costs and the fact that many tissues can be reproduced with it.39 Additionally, the high speed 
of the technology makes it possible to reproduce biological material, such as skin and 
cartilage, in situ.40 
Micro-extrusion printing, or bioplotting,41 is another method commonly used for 
bioprinting. In comparison to inkjet printing, this method prints the bioink as a continuous 
stream or beads of material rather than as individual droplets.42 This technology uses either 
pneumatic or mechanical means to control the flow.43 Micro-extrusion constitutes an 
                                                          
22 Sundaramurthi et al., supra n. 15, 16. 
23 Ibid., 16. 
24 Ibid., 16. 
25 Wang, Lee & Yeong, supra n. 16, 5. 
26 Murphy & Atala, supra n. 13, 779. 
27 Chua & Yeong, supra n. 14, 88; Mandrycky, Wang, Kim & Kim, supra n. 16, 427; Sundaramurthi et al., supra 
n. 15, 16. 
28 Sundaramurthi et al, supra n. 15, 16; Wang, Lee & Yeong, supra n. 16, 4.  
29 Sundaramurthi et al, supra n. 15, 17.  
30 Wang, Lee & Yeong, supra n. 16, 4.  
31 Mandrycky, Wang, Kim & Kim, supra n. 16, 423. 
32 Ibid. 422-434, 423. 
33 Murphy & Atala, supra n. 13, 775. 
34 Ibid., 775 – 776. 
35Mandrycky, Wang, Kim & Kim, supra n. 16, 423. 
36 Chua and Yeong, supra n. 14, 67. 
37 Generally, the more cells that are included in the bioink the higher its viscosity - Jana & Lerman, supra n. 16 , 
1505. 
38 Murphy & Atala, supra n. 13, 776; Chua & Yeong, supra n. 14, 71. 
39 Murphy & Atala, supra n. 13, 776. 
40 Ibid, 773, 776. 
41 Jana & Lerman, supra n. 16, 1507. 
42 Ibid., 1503-1521, 1507. See also Murphy & Atala, supra n. 13, 777. 
43 Murphy & Atala, supra n. 13, 773, 777; Jana & Lerman, supra n. 16, 1507. 
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elaboration of the inkjet technology without its pitfalls44 because bioinks with a higher 
viscosity can be used.45 Additionally, this technology allows more materials to be used as it 
could be applied at room temperature, which promotes the cross-linking of material. A 
negative element of micro-extrusion is the lesser degree of cell viability in comparison to 
inkjet printing.46 This is based on the pressure used, which affects cell membrane damage and 
can cause cell lysing.47 This problem can be addressed by applying less pressure but this 
would lead to loss of speed and printing resolution.48 
Finally, laser-assisted printing is another, but less common, method applied in 
bioprinting. However, it is gradually becoming more widely used.49 The technology uses “a 
pulsed laser source, a laser-focussing tool, a laser-energy-absorbing metallic ribbon film and a 
receiving substrate.”50 Printing is conducted by the laser, which pushes the bioink toward a 
collector substrate.51 Laser-assisted printing does not suffer from the pitfalls of inkjet printing. 
The lack of a nozzle means that clogging is not an issue52 and the technology is precise 
enough to print single cells in a row.53 In addition, this method allows for a large variety of 
material to be printed.54 
The applications that advances in the field of bioprinting may provide are mind-
boggling – to say the least. The most obvious field where this technology can be applied is 
regenerative medicine.55 Engineering of artificial organs would first and foremost alleviate the 
shortage of donor organs that are required.56 It could also put an end to the illegal trade with 
human organs.57  Additionally, the technology allows the use of autologous material, i.e. 
material that derives from the patient: the immune system would not reject an organ created 
from the patient’s own cells.58 Regeneration of functional skin and cartilage by using inkjet 
bioprinting is already possible.59 The skin could be used for severely burned victims.60 Inkjet 
and laser-assisted bioprinters have also been used to fabricate bone tissues.61 Bioprinting of 
nerve cells could be applied to treat diseases of the central nervous system such as 
Alzheimer’s and Parkinson’s disease.62 Jana and Lerman provide an overview of current 
research in relation to bioprinting.63 The table shows that the printing of blood vessels, bones, 
breast implants, cardiac valves, cartilage, but also more complex objects such as complete 
organs (ear, heart, kidney, liver, nerves and skin) are currently being researched on. 
                                                          
44 Mandrycky, Wang, Kim & Kim, supra n. 16, 425. 
45 Ibid., 422-434, 425; Murphy & Atala, supra n. 13, 777. 
46 Murphy & Atala, supra n.13, 777. 
47 Jana & Lerman, supra n. 16, 1508. 
48 Murphy & Atala, supra n. 13, 777. 
49 Sundaramurthi et al., supra n. 15, 13. 
50 Jana & Lerman, supra n. 16, 1507. 
51 Murphy & Atala, supra n. 13,778. 
52 Ibid. 773, 778. 
53 Jana & Lerman, supra n. 16, 1507. 
54 Ibid., 1503-1521, 1507 (adding that the coated film used for the printing process must be biologically 
individualized). 
55 Sundaramurthi et al., supra n. 15, 9. 
56 Ravi Birla, Introduction to Tissue Engineering: Applications and Challenges, 3 (1st ed., Wiley 2014). 
57 Katherine A. Smith, "Transplanting" Organ Donors with Printers: The legal and ethical implications of 
manufacturing organs, 49 (3) Akron Law Review 739, 767-768 (2016). 
58 Chua & Yeong, supra n. 14, 168. 
59 Murphy & Atala, supra n. 13, 776. 
60 This technology has also been conducted in vivo, i.e. by bioprinting skin directly into a wound or burned tissue 
– Murphy & Atala, supra n. 13, 782. 
61 Chua & Yeong, supra n. 14, 165. 
62 Sundaramurthi et al., supra n. 15, 19. 
63 Jana & Lerman,supra n. 16, 1510. 
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The applications, however, go further than direct applications within or on the human 
body. Such tissues can also be used in basic research and drug discovery64 or for pre-surgery 
planning on realistic bioprinted organs.65 Reproducing human tissue by bioprinting could end 
animal testing for regulatory approval.66 Additionally, meat and leather could be produced by 
using bioprinting.67 The technology promises to be exciting, with a wide array of applications. 
The current challenges that the technology faces are based on specific technical, material and 
cellular aspects.68 One challenge that bioprinting complex organs needs to tackle is the 
vasculature of such 3D constructs to create a viable organ.69 Nutrients and oxygen have to be 
supplied to create a viable organ.70 Once a certain degree of thickness of a tissue is reached 
then a vascular system is required.71 Aside from these technical challenges, the high costs of 
bioprinters will be likely to prohibit wider application of this technology.72   
 
 
2. A basic overview of the current patent landscape in bioprinting   
 
In the context of a growing field of technology, the question of patenting becomes 
increasingly relevant for the emerging bioprinting industry. While sharing elements of 
conventional 3D printing73, 3D bioprinting encompasses an entirely new and distinctive range 
of applications that may individually attract patent protection, such as new forms or improved 
versions of bioink74, or new and innovative bioprinting apparatuses.75 While patenting appears 
to be the intuitive intellectual property right used to exploit these new and research-heavy 
applications76, it must be borne in mind that other intellectual property and related rights may 
be similarly relevant: Trademarks, copyright and database protection along with trade secret 
law and unfair competition could be equally important measures for bioprinting 
entrepreneurs77 and will be addressed by other contributions. In the following section we focus 
on 1) main patent actors, stakeholders and activities; 2) most relevant fields of technologies 
and typical patent claim categories, and 3) the most likely future developments in the patent 
landscape. 
 
2.1 Main patent actors, stakeholders and activities 
 
                                                          
64 Murphy & Atala, supra n. 13, 782; Varkey & Atala, supra n.14, 278. 
65 Varkey & Atala, supra n. 14, 280. 
66 Chua & Yeong, supra n. 14, 166. 
67 Carolyn Mattick and Brad Allenby, The future of meat, 30 (1) Issues in Science and Technology 64, 65 (2013). 
68 Murphy & Atala, supra n. 13, 773, 781; Mandrycky, Wang, Kim & Kim, supra n. 16, 431; Lijie Grace Zhang, 
John Fisher and Kam Leong, 3D Bioprinting and Nanotechnology in Tissue Engineering and Regenerative 
Medicine, 73-74 (1st ed., Academic Press 2015). 
69 Chua & Yeong, supra n. 14, 164; Varkey & Atala, supra n.14, 295. 
70 Sundaramurthi et al., supra n. 15, 19. 
71 Xiaofeng Cui, Thomas Boland, Human microvasculature fabrication using thermal inkjet printing technology 
30 (31): 6221-7 Biomaterials (2009). 
72 Chua & Yeong, supra n. 14, 164. 
73 Tran, supra n. 12, 123, 137. 
74 Zhang, Fisher and Leong, supra n. 68, 356. 
75 John F. Hornick and Kai Rajan, The 3D Bioprinting Patent Landscape Takes Shape as IP Leaders Emerge 
(July 2016) available at: https://3dprintingindustry.com/news/3d-bioprinting-patent-landscape-takes-shape-ip-
leaders-emerge-84541 (accessed: 06 January 2017). 
76 Zhang, Fisher and Leong, supra n.68, 354. 
77 Robert W Esmond, Bioprinting: The patent landscape, available at: 
https://www.pharmafocusasia.com/strategy/bioprinting (accessed 6 January 2017). 
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Due to enormous and risky investments in this complex new technology, the bioprinting 
industry and researchers are increasingly relying on patent protection, with the number of 
patent applications expected to rise steadily.78 This is highlighted in a study by Hornick and 
Rajan, who have conducted a worldwide search for patents in the field of bioprinting.79 The 
search revealed a steady rise in patents and pending applications from 700 in April 2015 to 
almost 900 in June 2016; an increase of 36% in patent activity.80 Hornick and Rajan also 
demonstrated that while more than 100 companies from different countries around the globe 
are currently showing patent activity in the field of bioprinting, a few companies are clearly 
lying ahead of the others. The aforementioned market leader Organovo, which doubled their 
portfolio in the period investigated, as well as Wake Forest University and Philips, are the 
three top companies on Hornick and Rajan’s list.81 Generally, the patents investigated are 
owned by companies while some are held by the original inventor.82 But advances in 
technology along with regulatory approval of the medical applications of bioprinting are likely 
to shift the dynamics between the players in the field of bioprinting.83  
Another investigation into current patent activity by Robert W. Esmond showed that the 
majority of patent filings originate from the United States.84 The findings of this search pooled 
the patents granted into three main areas of relevant technologies with particularly vibrant 
patent activity. The following section provides a brief summary of these categories and the 
typical patent claims.   
 
2.2 Most relevant fields of technologies and typical patent claim categories 
 
Considering the different stages of development in bioprinting, the most relevant fields of 
technologies and typical patent claims can be distinguished into (1) a preprocessing or design 
phase, (2) a production phase, and (3) a post-production maturation phase.85  
In the preprocessing or design phase patent claims are typically directed to machines, 
methods and techniques used in bioimaging and computer aided design (CAD). One example 
that falls into this category is US patent No. 8579620 “Single-action three-dimensional model 
printing methods” (Exp. Date: May 30, 2031), which is assigned to the inventor Andy Wu.86 
This patent claims systems and methods for single-action printing of 3D physical models from 
a three or n-dimensional image data set. It describes geometric representations of different 
physical models and discloses complex data conversion processes that convert input image 
data into geometric representations compatible with third party 3D printers. The patented 
technology uses printing templates to encapsulate complex geometric representations and 
complicated data conversion processes from users for fast and simple 3D physical model 
printing applications.87  
In the production phase some of the most important patents issued are directed to 
bioinks, in particular hydrogels, biopaper and bioprinting apparatuses as such. One example is 
                                                          
78  Seung-Schik Yoo, 3D-printed biological organs: medical potential and patenting opportunity, 25 (5) Expert 
Opinion on Therapeutic Patents, 507, 510 (2015). 
79 Hornick and Rajan, supra n. 75.  
80 This value relates to the observable, i.e. published patents and application while the actual value could be 
higher due to unpublished patent applications - Hornick and Rajan, supra n. 75. 
81 Hornick and Rajan, supra n. 75. 
82 Ibid. 
83 Ibid. 
84 Esmond, supra n. 77. 
85 Ibid. 
86 Andy Wu, Single-action three-dimensional model printing methods, US 8579620 B2, 
http://www.google.com/patents/US8579620 (2013).  
87 Ibid. 
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US patent No. 8143055 “Self-assembling multicellular bodies and methods of producing a 
three-dimensional biological structure using the same”.88 The patent claims appear to cover 
bioprinted tissues and organs containing patterned discrete filler bodies that resist migration 
and ingrowth of patterned multicellular bodies containing living cells. These filler bodies may 
include sacrificial hydrogels that form tubular engineered blood vessels inside tissues and 
organs.89 This patent, which was also filed at the European Patent Office and in Australia, 
Canada, China, Japan and South Korea, was originally assigned to The Curators Of The 
University Of Missouri and expires on June 24, 2029. However, the University of Missouri 
had entered into an agreement with Organovo, which now holds the exclusive license in all 
fields to multiple patent families, including this issued patent and future continuation patents 
derived from the same application.90 
Another example is British patent GB2478801 directed to “Multilayered Vascular 
Tubes” (Expiration date March 16, 2031) which was also filed in Canada, China, European 
Patent Office, Israel, Japan, South Korea, Russia, and the United States.91 It is assigned to 
Organovo Inc. and claims inter alia “an engineered multilayered vascular tube comprising an 
outer layer of differentiated adult fibroblasts, at least one inner layer of differentiated adult 
smooth muscle cells and differentiated adult endothelial cells, which have particular 
features.”92 This patent describes in detail how the engineered multilayered vascular tube is 
constructed and produced by laying manually elongate cellular bodies and elongate bodies of 
gel matrix. The patent also describes the use of a bioprinter to make the same structure.93  
In the post-production and maturation phase, additional patenting prospects might 
emerge in advanced organ production. These include so-called maturongens, i.e. biochemical 
and physical factors that accelerate tissue maturation94, or so-called bioreactors, i.e. new 
technologies, materials and machines that provide nutrients to cells in the post-print phase.95 
The aforementioned Esmond study, however, only identified pending patent applications that 
                                                          
88 Gabor Forgacs, Francoise Suzanne Marga, Cyrille Norotte, Self-assembling multicellular bodies and methods 
of producing a three-dimensional biological structure using the same, US 8143055 B2, 
http://www.google.com/patents/US8143055 (2012). 
89 Cf. Esmond, supra n. 77. What is claimed is: 1. A three-dimensional structure comprising: a plurality of 
multicellular bodies, each multicellular body comprising a plurality of living cells cohered to one another; and a 
plurality of discrete filler bodies, each filler body comprising a biocompatible material that resists migration and 
ingrowth of cells from the multicellular bodies into the filler bodies and resists adherence of cells in the 
multicellular bodies to the filler bodies, wherein the multicellular bodies and filler bodies are arranged in a 
pattern in which each multicellular body contacts at least one other multicellular body or at least one filler body. 
90 Press Release of 9 July 2012, Organovo Announces Two Issued Patents, First Company Patent and Key 
Founder Patent, https://www.sec.gov/Archives/edgar/data/1497253/000119312512297696/d379308dex992.htm  
(accessed 10 December 2016). 
91 See Covalent Data, Multilayered vascular tubes, GB 2478801 B, 
https://covalentdata.com/patent/GB2478801B, referring also to patents: AU2011227282B2, CA2793205C, 
CN102883680B, CN105749349A, EP02547288A2, GB2489081B, HK1159682A1, mJP2016052527A, 
JP5950899B2 and KR20130007610A. 
92 Claim 1 reads: “1. An engineered multilayered vascular tube comprising an outer layer of differentiated adult 
fibroblasts, at least one inner layer of differentiated adult smooth muscle cells and differentiated adult endothelial 
cells, and having the following features: (a) a ratio of endothelial cells to smooth muscle cells of 1:99 to 45:55; 
(b) the engineered multilayered vascular tube is compliant; (c) the internal diameter of the engineered 
multilayered vascular tube is 6 mm or smaller; (d) the length of the tube is up to 30 cm; and (e) the thickness of 
the engineered multilayered vascular tube is substantially uniform along a region of the tube; provided that the 
multilayered vascular tube is non-innervated and free of any pre-formed scaffold”. 
93 Lens.org, Multilayered vascular tubes, https://www.lens.org/lens/patent/GB_2478801_B. 
94  See the definition provided in Paulo Jorge da Silva Bartolo, Innovative Developments in Virtual and Physical 
Prototyping: Proceedings of the 5th International Conference on Advanced Research in Virtual and Rapid 
Prototyping, Leiria, Portugal, 28 September - 1 October, 2011, 127 (CRC Press 2011); See also Ibrahim Tarik 
Ozbolat, 3D Bioprinting: Fundamentals, Principles and Applications, 319 (Academic Press 2016). 
95 Yoo, supra n. 78, 507, 509; 510. 
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cover these types of technologies.96 Instead of covering fully functioning organs or more 
advanced maturation systems, current patents rather cover the production of organ cells, such 
as 9,442,105 “ Engineered liver tissues, arrays thereof, and methods of making the same”97 
assigned to Organovo Inc. in 2014, or technology that might one day provide the foundation 
for the transplantation of bioprinted organs. One example is US 8747880 “Engineered 
Biological Nerve Graft, Fabrication and Application Thereof”. Once again the patent, which 
expires on May 28, 2031, has been originally assigned to The Curators Of The University Of 
Missouri with Organovo being the most likely licensee.  It covers an engineered three-
dimensional nerve graft that may be made using bioprinting techniques. The structure is 
suitably a graft that facilitates restorative axon growth when the graft is implanted between the 
proximal and distal stubs of a severed nerve in a living organism. 98 
 
2.3 What lies ahead in the patenting landscape 
 
As described above, the foundational technology for bioprinting has already resulted in many, 
partially overlapping, patents that are predominantly assigned to a few market-leaders, such as 
Organovo Inc. Yet several missing engineering components for the ultimate creation of 
printed biological organs indicate that much room remains for further patentable 
improvements.99 After all, the production of complete organs is still in a state of infancy. The 
complicated nature of human organs, in addition to the legal and ethical requirements for safe 
implantation into the human body, would require significant research and development to 
produce marketable bioprinted organs.100 As is further pointed out by Seung-Schik Yoo, this 
also suggests the possibility for further patenting and licensing opportunities from different 
sectors of the economy. In particular, Yoo asserts that so many technical aspects of organ 
printing remain unresolved that it is unrealistic to expect intellectual property in this area to be 
dominated by a monopolist or an oligarchy. He fully expects biotechnological advances to 
result in human organ production in a wider context of multiple uses of printed organs and 
tissue, in turn associated with an ever-growing volume of patent applications. 101      
 
However, a caveat needs to be added: Based on the current state of the art, it would take many 
years, probably even decades, of research and development to have marketable bioprinted 
organs with high-order functionality that fulfill the ethical and legal requirements for ultimate 
use in humans.102 Some researchers have even questioned whether it will be technically 
possible to create a functioning bioprinted organ: 
                                                          
96  1. A multicellular construct consisting essentially of: a multicellular region comprising: a plurality of living 
cells cohered to one another to form an elongate graft for restoring neural connection between the ends of a 
severed nerve; a plurality of a cellular channels extending axially through the multicellular region; and wherein 
the multicellular construct does not comprise any scaffold material at the time of implantation into a living 
organism having a nervous system. 
97 Benjamin R. Shepherd, Engineered liver tissues, arrays thereof, and methods of making the same, US 
20140274802 A1, http://patents.com/us-9442105.html.  
98 Gabor Forgacs et al., Engineered biological nerve graft, fabrication and application thereof, US 8747880 B2  
http://www.google.com/patents/US8747880. 
99 Mohsan Alvi, Matthew Duckett  & Robert Gleave, 3D Bioprinting of human transpant organs – A patent 
landscape, 15, http://www.collerip.com/userfiles/739.pdf.  
100 Yoo, supra n.78, at 507. 
101 Ibid., 510 
 102 Ibid., (adding that 3D bioprinting could nevertheless “be used to exploit a few niche applications, with less 
stringent FDA-related regulations, which can be readily put to practical use. These include, but are not limited to, 
applications to create: i) the artificial skin constructs as testing beds for cosmetic industries (3D bioprinting can 
readily be adapted to create skin layers with different phenotypes, along with skin blemishes and colors); ii) the 
3D tissue structures/mini-organs, replicating major key components of liver/kidney tissues that have relevance to 
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For example, Dr. Darryl D’Lima, a researcher at the University of Manchester in Britain, 
has been quoted as saying that “Nobody who has any credibility claims they can print 
organs, or believes in their heart of hearts that will happen in the next 20 years.” And, there 
have been reports that Dr. Gabor Forgacs, inventor of the Missouri patents and Scientific 
Founder at Organovo, has questioned whether the days of printing organs will ever come.103 
 
Before the first fully functional bioprinted organ can be made and approved by regulatory 
authorities, such as the European Medicine Agency (EMA) and the US Food and Drug 
Administration (FDA), it is thus highly likely that many basic patents will have expired. 
Moreover, many countries have codified various exceptions to patent infringement, such as 
research and/or experimental use exemptions.104 In both Europe and the United States, the law 
provides, for example, for an exemption to patent infringement when the patented item or 
material is tested for obtaining market approval from the EMA or the FDA.105 Thus, in many 
countries, some research and clinical testing of a patented bioprinted organ or tissue could be 
carried out without infringing patents. However, due to rather vague wording in the legislation 
and different interpretations in national case law, the precise scope of such exemptions varies 
and is hence rather unclear. Unsurprisingly, this provides rich fodder for debates in academia 
and jurisprudence, which often call for harmonized approaches with regard to such types of 
exemptions.   
Be that as it may, overall it can assumed that if the technical and regulatory challenges 
to making and using bioprinted tissues and organs are overcome, the future of innovation in 
bioprinting technology will be very bright and patenting activities will continue.106 Another 
question is of course how far future advances in bioprinting technology would comply with 
the regulatory framework for technological uses and if they would meet the basic patent 
criteria or fall under the exceptions and exclusions from patentability. 
 
 
3. Basic US and European patentability criteria and bioprinting 
 
The above concise overview on the current patent landscape and the typical claims provide the 
very first understanding of what categories of patents are typically being granted or applied 
for. Patent landscaping may also reveal useful information about the main stakeholders in the 
field and where the area is heading. At the same time, it also became clear that there are many 
unknowns with regard to pending applications and that the landscape might be rapidly shifting 
due to new technological developments, new collaborations and strategic alliances. Moreover, 
the patentability of future developments and applications, involving cloned organs, stem cells 
and other biologically engineered tissues, remains problematic and raises many questions and 
uncertainties.  
It is evident that the interplay between patent law and technological development is two-
fold. On the one hand, bioprinting application will challenge patent law and other legal 
frameworks, which might result in new court decisions or even legislative developments. On 
                                                                                                                                                                                      
systemic toxicity/efficacy screening of pharmacological drugs in high-throughput fashion; and iii) the in vitro 
tumor tissue models that enable the examination of tumor infiltration, growth and metastasis”. 
103 Cf. Esmond, supra n. 77.    
104 Cf. Hans Rainer Jaenichen & Johann Pitz, Research exemption/experimental use in the European Union: 
patents do not block the progress of science, 5(2):a020941 Cold Spring Harb Perspect Med. (2014); see also 
Alicia A. Russo and Jason Johnson, Research Use Exemptions to Patent Infringement for Drug Discovery and 
Development in the United States, 5(2):a020933 Cold Spring Harb Perspect Med. (2015).  
105 See András Kupecz et al., Safe harbors in Europe: an update on the research and Bolar exemptions to patent 
infringement, 33 Nature Biotechnology, 710–715 (2015). 
106 Ibid. 
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the other hand, the applicable rules on patentability and regulations will certainly have an 
impact on the financing of research and might accordingly direct research focus into particular 
lucrative areas.    
This illustrates the importance of understanding how current patent law applies to 
bioprinting technologies. Hence, this section will briefly describe the current legal frameworks 
and requirements for patentability that we consider to be most relevant for bioprinting 
technology. The patent landscape discussed above showed that bioprinting contains an array 
of different stages which encompass different fields of technology such as biochemistry, 
biotechnology, computer sciences and mechanics. We will focus our analysis on selected 
aspects regarding the “biological” material and processes involved in bioprinting relating to 
the production and post-production phase of bioprinting, rather than dealing with 
“mechanical” inventions stemming from this technology. This is because biological material 
poses more issues for patenting than mechanical devices. Furthermore, our analysis will 
concentrate on US patent law and the European Patent Convention (EPC). We will also touch 
upon relevant stipulations in the EU Biotech Directive. However, the analysis will concentrate 
on the legal framework applicable at the European Patent Office (EPO), rather than national 
patent laws. Section 3 will focus on basic patent criteria for product and method claims. 
Section 4 will deal with the particularly important questions of morality and ordre public in 
patent law and will analyse whether bioprinting technologies will pose new challenges to the 
existing legal framework. 
 
3.1 Product claims 
 
As indicated above, product claims on bioprinting technologies might encompass the 
machines and mechanical parts that are being used in the bioprinting process itself. But they 
might also be directed to innovative biological printing material, such as bioink, or the end-
product made from biological material and resulting from the bioprinting process. As 
mentioned, strictly “mechanical innovation” relating to bioprinting machines and mechanical 
processes might not lead to any extraordinary issues in the assessment of the basic 
patentability criteria, such as patent eligibility, novelty, inventive step/nonobviousness, 
industrial application/utility and sufficient disclosure. The patent system has dealt with these 
types of inventions for hundreds of years. This is why our brief analysis will focus on the 
biotechnological aspects of bioprinting innovation, where patentability issues are far more 
complex. 
 
3.1.1 US107 
 
Unlike European patent legislation,108 US patent statutes have traditionally not defined what 
sorts of inventions or discoveries fall outside the scope of patentability.109 It has thus been the 
province of the courts to establish limits for subject matter that may not be granted patent 
protection. The generally accepted explanation is that these are Constitutional limitations 
                                                          
107 As for the introduction to section 3.1.1, cf. Robert M. Schwartz & Timo Minssen, Life after Myriad: The 
Uncertain Future of Patenting Biomedical Innovation & Personalized Medicine in an International Context, 
2015 (3) Intellectual Property Quarterly, 189-241, 190. 
108 See e.g. the exceptions to patentability of Art. 52(2)–53 EPC. However, the interpretation of these 
ambiguously phrased exceptions is also highly controversial. European debates are further complicated by the 
contentious definition of the term “invention” in i.a. Art. 52 (1) EPC and the stipulations in the Biotech Directive 
98/44/EC.  
109 Until recently nuclear weapons were the only invention-category completely excluded from patent eligibility 
(albeit not from a prize-system). However, this exclusion is not codified in the Patent Act, but in the Atomic 
Energy Act. 42 U.S.C. § 2181(a) (2000). 
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based upon the framers’ intent in enacting the Patent Clause.110 Although several bills had 
attempted to exclude genes and proteins from patent protection,111 the 2011 America Invents 
Act (AIA)112 only introduced very few exceptions, which will be considered in section 4. 113 
Hence, fundamental questions of patent eligibility are principally still left relatively open and 
for the courts to decide.  
Until a few years ago, US Courts kept this threshold rather low as exemplified by the 
decision in Diamond v. Chakrabarty (1980)114 which held that any man-made product or 
process could be patented if it did not claim “principles of nature, natural phenomena, abstract 
ideas or mental processes.” Chakrabarty thus identified “human intervention” as the key to 
patentability. For many years, the “human intervention” standard was interpreted in a rather 
patent-friendly way. Human genes and proteins, for example, were held to be principally 
patent-eligible, as long as some human inventive activity was involved, such as new 
identification and isolation of a naturally occurring gene from its natural environment. 
On June 13, 2013, however, the threshold was raised considerably when the US 
Supreme Court decided the Myriad gene patent case115. In a unanimous judgment, the Court 
held that patent claims directed to isolated genomic DNA are identical to the naturally 
occurring sequence and thus unpatentable “products of nature”. Because its genetic 
information was neither created nor altered, DNA did not qualify as a product of human 
ingenuity and because isolating DNA from its surrounding genetic material did not 
significantly add to DNA’s natural state, it did not qualify as non-naturally occurring.116 This 
decision affects all isolated “products of nature”, including genes, gene fragments, and other 
naturally occurring nucleotide sequences, as well as naturally occurring amino acid sequences, 
including peptides, ligands, and proteins. Consequently, Myriad may have an impact on 
bioprinting patent portfolios, although it is still not entirely clear how much modification is 
required to render a molecule sufficiently distinct from naturally occurring counterparts.  
It is clear, however, that Myriad does not directly affect the patentability of cDNA or 
sufficiently modified compounds, such as synthetic DNA and other synthetically produced 
biological material. Moreover, the most recent USPTO guidance and new Federal Circuit 
decisions provide hints on how the new eligibility standard can be met.117 To avoid a “product 
of nature” rejection, a claim must satisfy a two-prong test: 
  
(1) a product of human ingenuity, and 
(2)  nonnaturally occurring.  
 
Accordingly, the patentability of bioprinting depends on whether a bioprinted product is a 
product of human ingenuity and nonnaturally occurring.  While some of the base materials 
used in printing may be naturally produced, in the same way as nucleotides in cDNA can be 
                                                          
110 E.g. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) at 315.  
111 In 2007, for example Michael Crichton teamed up with Lori B. Andrews, from the Chicago-Kent College of 
Law, and found support by Representatives Xavier Becerra and Dave Weldon, who unsuccessfully introduced a 
Bipartisan Bill (HR 977) in the 110th Congress to restrict future patenting of genes and proteins. 
112  The HR 1249 Leahy-Smith America Invents Act (2011). 
113 The HR 1249 introduced an immediately effective ban on patents covering tax strategies and/or claims 
“directed to or encompassing” human organisms (see section 33). These will apply to all pending applications 
(Dr. Frankenstein must now rely on trade secrets).  
114 Diamond v. Chakrabarty, supra n. 110 (holding that a genetically engineered bacterium created by the 
inventor’s process was a patentable “manufacture” under §101 of the U.S. Patent Act). 
115 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). 
116 Jasper L. Tran, Patenting Bioprinting Harvard Journal of Law and Technology Digest, 2015 symposium, 2, 
https://ssrn.com/abstract=2603693 (2015). 
117 The current 2016 USPTO patent eligibility guidelines are available at: https://www.uspto.gov/patent/laws-
and-regulations/examination-policy/subject-matter-eligibility (accessed 10 December 2016). 
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naturally produced, technically, anything related to bioprinting is a result of human ingenuity: 
both bioprinting processes and bioprinted products are man-made. The more complex prong is 
proving that a bioprinted product is non-naturally occurring.118  
State of the art bioprinting technology does not yet allow for perfect reproduction of 
human organs; marked differences exist between real organs and bioprinted ones.119 Current 
bioprinted human living tissues are functionally similar to but structurally different from real 
human living tissues. Until scientists can bioprint structurally similar living tissues, bioprinted 
products are different enough from their naturally-occurring analogs to be patent-eligible 
subject matter.120 However, should the technology develop in the future to allow for the 
perfect replication of human organs, the line between patentable and unpatentable subject 
matter could blur significantly.121 Such perfectly replicated organs could be considered 
analogous to “very short series of DNA [that] have no intervening introns to remove when 
creating cDNA” which “may be indistinguishable from natural DNA” and thus not patent-
eligible under § 101.122 But what about the bioprinting of biological clones?  
In this context, the Federal Circuit decision in In re Roslin Institute needs to be 
observed, where it was held that a clone which was an exact genetic copy of a naturally 
existing sheep was not patent-eligible subject matter.123 Yet, according to some US 
commentators, this would not necessarily prevent the patentability of a clone-printed, man-
made and non-human organism. As it is pointed out by Jasper L. Tran: 
 
There is no reason to expect that a clone made by any other process would be treated differently. 
However, in the wake of Chakrabarty, numerous patents have been filed on transgenic organisms. 
For example, U.S. Patent No. 8,088,968 claims a transgenic animal (e.g., a mouse) and its 
tissues.124Accordingly, cloneprinting of a naturally existing organism is likely not patentable, but 
cloneprinting of a man-made organism (i.e., a genetically engineered animal) could likely be 
patentable.125 
 
The patenting of clones of entire human persons (including fetal, embryonic states and 
chimera), however, would not be possible due to section 33 AIA, which will be addressed in 
section 4. 
 
3.1.2 Europe 
 
The most essential patentability criteria in the European Patent Convention (“EPC”)126 are 
summarized in Article 52(1) EPC 2000, which provides: 
 
European patents shall be granted for any inventions, in all fields of technology, provided that 
they are new, involve an inventive step and are susceptible of industrial application. 
 
                                                          
118 Tran, supra n. 116. 2. 
119 David Wang, Are 3D Printed Tissues and Organs Patentable? Columbia Science and Technology Law 
Review Blog, http://stlr.org/2015/10/07/are-3d-printed-tissues-and-organs-patentable/ (accessed 10 December 
2016). 
120 Tran, supra n, 116, 2.  
121 Wang, supra n. 119 
122 Ibid (citing Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S.Ct. 2107, 2116 (2013), 2219). 
123 In re Roslin Institute 750 F.3d 1333 (Fed. Cir. 2014). 
124 Tran, supra n. 116, 2. 
125 Ibid (internal citation omitted). 
126 European Patent Convention of 5 October 1973 as revised by the Act revising Article 63 EPC of 17 December 
1991 and the Act revising the EPC of 29 November 2000 (“EPC”). Text as adopted by decision of the 
Administrative Council of 28 June 2001. See also OF 4/2007 Revision of the European Patent Convention (EPC 
2000). 
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Considering the wording of the article, it is clear that despite having to meet the most basic 
patent criteria, such as novelty, inventive step and industrial application, patents and patent 
applications in bioprinting must be based on a “technical invention”. This is also confirmed by 
the implementing regulations to the EPC, which emphasize that the invention must have 
technical features (Rule 43(1)), which relate to a technical field (Rule 42(1)(a)) and are 
concerned with a technical problem (Rule 42(1)(c)). Although the EPC does not explicitly 
define the concept of “inventions” as such, it is evident from these provisions that the 
“technicality” of inventions is a crucial prerequisite for meeting European patent eligibility 
standards. Hence it comes as no surprise that several court decisions in EPC contracting states 
have elaborated on the issue.127  
However, and in contrast to most of the codified US patent law, Articles 52(2) and 
52(3) of the EPC explicitly codify exclusions, which are not considered to be inventions, i.e. at 
least if they are claimed “as such” . These exclusions are used to reject claims that are abstract 
in nature (discoveries) or non-technical in nature (scientific theories or methods for 
performing mental acts). 
Most bioprinting processes and bioprinted products are the result of a technical man-
made process with the help of man-made machinery and would thus fulfill the European 
technicality requirement. But what about the naturally occurring compounds in bioink and 
other bioprinted products? 
With respect to isolated biological compounds, such as DNA sequences and proteins, the 
main provisions of the EU’s Biotechnology Directive 98/44/EC were quickly incorporated 
into the Implementing Regulations (“IR”) to the EPC by a decision of the Administrative 
Council of the European Patent Organization (“EPOrg”) of June 16, 1999.128 Thus, the 
patentability of biotechnological inventions is assessed by the EPO based on a one-to-one 
implementation of the EU Biotech Directive, i.e. although the EPO is not formally bound by 
European Community law. Rule 23(e)(2) (now Rule 29 (2) EPC 2000) of the Implementing 
Regulations now defines which biological material originating from the human body may be 
patented. Like Article 5 (2) of the Biotech Directive it states that: 
 
(2) An element isolated from the human body or otherwise produced by means of a technical 
process including the sequence or partial sequence of a gene may constitute a patentable invention, 
even if the structure of that element is identical to that of a natural element. 
 
But even before the relevant stipulations of the Biotech Directive were incorporated into the 
EPC, the patent-eligibility of isolated biological material had already been unambiguously and 
clearly confirmed by earlier EPO case law. For example, in decision T 272/95 
Relaxin/HOWARD FLOREY INSTITUTE129 concerning a DNA fragment encoding human H2-
preprorelaxin with a specific amino-acid sequence useful during the child birth-process, the 
EPO appeared to lay the issue to rest. The opponent had argued that the essence of the 
invention was no more than elucidation of the genetic sequence of the H2-relaxin gene. In the 
view of the opponent this was no more than a discovery of the characteristics of a substance 
which had existed in nature probably for many thousands of years. In granting the patent the 
EPO rejected inter alia these specific arguments based on the understanding that an isolated 
gene contains technical information, in the sense that the aspect of “isolation” is considered to 
be the result of technical processes used to identify, purify and classify it, techniques which 
                                                          
127 See e.g. Biogen Inc. v. Medeva Plc. Hepatitis-B-virus, 1997: R.P.C. 1 (41–42); Red Dove (Rote Taube), X ZB 
15/67: Federal Supreme Court, 1969. 1 I.I.C. 136, 1970 (“Lehre zum planmässigen Handeln” = “methodological 
teaching”). 
128 OJ EPO 1999, p. 437-440 and 573 ff. 
129 See T0272/95 Relaxin/Howard Florey Institute (Unreported, Boards of Appeal, European Patent Office), 23 
October 2002), [4], [6]–[7]. 
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human beings alone are capable of carrying out in a methodological manner and which nature 
is incapable of accomplishing by itself. 130 
The same reasoning, now codified in Rule 29 (2) of the Implementing Regulations to 
the EPC 2000, has also been applied in various EPO decisions on Myriad’s BRCA1 patents 
related to claims for diagnosing a predisposition for breast and ovarian cancer in a human 
subject.131 In addition it should be noted that the EPC – apart from certain specific 
exceptions132 – does not contain any categorical use restrictions for product protection. There 
are thus no technology-specific provisions in the EPC that categorically limit the protective 
scope of gene- or protein-related patent applications to the uses specified in the claims – in 
contrast to some national European jurisdictions.133 Under Rule 42(1) (f) EPC 2000,134 it is 
sufficient if the applicant provides the industrial applicability in the description of the 
invention, and must only do so explicitly when it is not obvious from the description or nature 
of the invention. This basic condition is now specified particularly for gene sequences and 
partial gene sequences in Rule 29(3) EPC 2000, which fully corresponds to Article 5(3) of the 
Directive.  
Isolated genomic DNA per se is thus, in contrast to the current US approach, 
principally patentable both before the EPO and national patent offices as no office 
distinguishes between naturally occurring genomic DNA and corresponding cDNA. 
Accordingly, it may be concluded that, although the patentability of isolated biological 
material remains controversial in Europe, the decision by the US Supreme Court to exclude 
naturally occurring biological compounds from patent-eligibility appears to be in conflict with 
current European practice.  
Hence, most bioprinting products would in principle be patent-eligible in Europe, 
unless they fall under the exemptions from patentability, which will be dealt with in sections 
3.2 and 4. In particular the morality clauses in European Patent Law could turn out to be a 
major obstacle for the patentability of organs and clones. 
 
 
3.2 Method claims 
 
Even when bioprinting products might not pass the US and European patent eligibility 
requirements, applicants could still consider seeking patent protection for process claims 
rather than product claims. Instead of covering ineligible products, a bioprinting process claim 
could be limited to printing activities and thus pass the bar. Provided that ineligible products 
are not mentioned in process claims, and the relevant claims do not depend on bioprinted 
ineligible products, such claims can be patentable.135 Or, in other words: the 3D printing 
process itself does not necessarily violate the principle of no patent for human organisms per 
                                                          
130 Ibid. See also Article 5 (2), as well as Recitals 20 and 21 in the Biotech Directive. Cf. Howard Florey/Relaxin 
[1995] EPOR 541. 
131 Cf. T 1213/05 Breast and ovarian cancer/UNIVERSITY OF UTAH (EPO 27 September 2007); T 0666/05 
Mutation/UNIVERSITY OF UTAH (EPO 13 November 2008 & T 0080/05 Method of diagnosis/UNIVERSITY OF 
UTAH (EPO 19 November 2008). 
132 For instance, patent applications in respect of medicinal indications pursuant to Article 54(4) and (5) EPC, and 
product claims that can be defined solely through their function. See for more: Timo Minssen, KliFoRe, Heft Nr. 
3 and  4 (2008), p. 93 ff, available at: http://jura.ku.dk/english/staff/research/?pure=en%2Fpublications%2Fes-
bleibet-dabei-eine-schwedische-stellungnahme-zur-europaischen-debatte-uber-den-absoluten-erzeugnisschutz-
bei-der-dnapatentierung--teil-1(35c50066-1f9c-4757-8b52-17a18e7922e5).html (accessed 30 January 2017). 
133 Cf. Rainer Moufang's contribution to the 15th European Patent Judges' Symposium, Lisbon, 14-18 September 
2010: Use and purpose limitations in patent claims, OJ EPO Special edition 1 (2011). 
134 Rule 42(1)(f) “[The description] shall indicate explicitly, when it is not obvious from the description or nature 
of the invention, the way in which the invention is industrially applicable.” 
135 Cf. Tran, supra n. 116, 2.  
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se notwithstanding the mere possibility that 3D-printed human tissue could theoretically be 
used in unpatentable products later in the process.”136 
 
3.2.1 US  
 
At first sight, two recent US Supreme Court cases addressing the patent-eligibility of method 
claims appear to be relevant for bioprinting: 
In 2012, the US Supreme Court issued a unanimous decision in Mayo v. Prometheus137 
invalidating patent claims for diagnostic methods under the “laws of nature, natural 
phenomena, and abstract ideas” exception to 35 U.S.C. § 101’s standards for patent-eligibility. 
Writing for the Court, Justice Breyer invalidated the relevant claims138 because they “set forth 
laws of nature—namely, relationships between concentrations of certain metabolites in the 
blood and the likelihood that a dosage of a thiopurine drug will prove ineffective or cause 
harm.”139 The Court further held that the steps of “administering” the drugs, telling the 
physician to take the laws of nature into account, and “determining” the metabolite level, in a 
specific order of steps were “well-understood, routine, conventional activit[ies]…” adding that 
they comprised “nothing beyond the sum of their parts...”.140 While the additional steps recited 
in the processes claimed in the case were not to  be considered natural laws as such, a patent 
applicant would have been required to add more in order to transform them into patent-eligible 
claims. Thus, the Supreme Court held that in order to transform an unpatentable law of nature 
into a patent-eligible application of such a law, it is not sufficient to simply state the law of 
nature and add the phrase “apply it”. The Court held that appending conventional steps, 
specified at a high level of generality, to laws of nature, natural phenomena and abstract ideas 
could not render those laws, phenomena, and ideas patent-eligible. 
Yet, since bioprinting processes are created by scientists and are carried out by 
machines that are not found in nature, most bioprinting processes would normally not qualify 
as a “law of nature” under the Prometheus approach. Therefore, Mayo usually does not apply 
to bioprinting process claims.141 But what about claims concerning the software that is used 
in bioprinting machines? 
In 2014, the Supreme Court considered the patentability of software patents in Alice 
Corp. v. CLS Bank142. In Alice, the Supreme Court set forth a two-step process for assessing 
patent-eligible subject matter in the context of computer-related inventions: 
 
1) Initially, determine whether the patent claim at issue is directed to an abstract idea. 
2) If so, consider whether the claim elements individually or in combination “transform” the claim into 
a patent-eligible invention.   
 
The Court described the test as a quest for an “inventive concept” to ensure that the patent 
amounts to “significantly more” than an abstract idea. For the second step, the Supreme Court 
                                                          
136 Ibid. (Providing examples of this approach by referring to U.S. Patent No. 7051654 B2 claiming a method of 
“forming an array of viable cells” & U.S. Patent No. 8691974 B2 claiming a method of “producing 3-D nano-
cellulose based structures.) 
137 Mayo v. Prometheus, 132 S.Ct. 1289, 1291–92 (2012). 
138 The claims at issue in the patents were directed to three essential steps in a process by which a doctor (1) 
administered the drug, (2) determined the metabolite levels in the blood, and (3) a ‘wherein’ step which described 
the likely effects of a dose and respectively indicated a need to increase or decrease the dosage. See e.g. 
Prometheus Laboratories’ US Patent No. 6355623 B2 and US Patent No. 6680302 B2. 
139 Mayo v. Prometheus, supra at 137, 1296. 
140 Ibid., 1297-1298. 
141 Tran, supra n. 116, 2 (adding: “Unfortunately, besides Mayo, there is no closer case where the process was 
patentable despite being closer to a law of nature than bioprinting is.”). 
142 Alice Corp.  v. CLS Bank, 134 S.Ct. 2347, 2357–59 (2014). 
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in Alice clarified that “the mere recitation of a generic computer cannot transform a patent-
ineligible abstract idea into a patent-eligible invention.”  Moreover, the Court decided that 
claiming well-understood, routine, and conventional features specified at a high level of 
generality does not suffice for an “inventive concept.”  However, the Court gave little 
guidance beyond those rather extreme patterns and did not specify the precise delimitations of 
the ‘abstract ideas’ category. 
Be that as it may, 3D printing and bioprinting do not fundamentally depend on 
software, but print using an electronic blueprint—i.e., a CAD file. Thus, at the current state 
of the art neither Prometheus nor Alice necessarily affects the patentability of 3D printing 
and bioprinting.143 
Yet this might change. So far, most bioprinting technologies lacked biologically 
sophisticated software and other bioinformatics tools.144 But in the future the patentability of 
more sophisticated software mimicking biological processes and correlations might become 
more important for bioprinting technologies. Rapid advances in systems biology and synthetic 
biology in combination with the evolution of data-based applications are now providing 
increasingly powerful tools. It can be assumed that the combined use of Big Data in 
bioinformatics will enable the field's next wave of breakthroughs. While a more detailed 
analysis of these developments falls outside the scope of this paper, these technological 
developments will certainly have to be observed very carefully. It might therefore make sense 
to have a look at the European approach in this area. 
 
3.2.2 Europe145  
 
As mentioned in section 3.1.2 most bioprinting processes are the result of – or part of – a 
technical man-made process with the help of man-made made machinery and would thus 
fulfill the European requirements in Article 52 (1) - (3) . But what about software used in 
bioprinting? 
 In comparison, the European eligibility doctrine with regard to software, data-related 
inventions and diagnostic methods appears to be more flexible than in the US, i.e. despite the 
existence of an express provision on their excludability. Article 52 (2) of the EPC146 famously 
recites a list of ‘non-inventions’, including abstract ideas, scientific theories, mathematical 
methods and computer programs, that are excluded ‘as such’. The reading of this last 
condition has led to a de-minimis application of the provision.  
“Technical character” is synonymous with invention in EPO Board of Appeals (BoA) 
case law; any demonstration and degree of ‘technical character’ passes the patent eligibility 
threshold. The role of the technical feature is irrelevant; to the point that the mere use of 
technical means, such as a computer, may render a patent claim eligible. Accordingly, the 
question asked for computer-based methods that could be used in bioprinting is: does the 
method achieve a technical effect, or has it only non-technical aspects, e.g. aesthetic or 
economic?147  
Mere games or business methods, for example, are not patentable148, but a method to 
analyse DNA in silico is.149 This also applies to simulations or modelling as long as the result 
                                                          
143 Tran, supra n. 116, 2. 
144 Leckart, supra n. 2. 
145 See also T. Minssen & J. Pierce, Big Data and Intellectual Property Rights in the Health and Life Sciences, in: 
G. Cohen, H. Fernandez Lynch, E. Vayena & U. Gasser (red.), Big Data, Health Law, and Bioethics, (Cambridge 
University Press (forthcoming in 2017)). 
146 Convention on the grant of European Patents (European Patent Convention), (5 October 1973),1065 UNTS 
199 (‘EPC’). 
147 T 208/84 Computer-related invention (EPO 15 July 1986) (VICOM). 
148 T 931/95 Control of a pension fund system (EPO 8 September 2000) (PBS). 
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is a teaching which can be used to achieve technical effects in the real world. For instance, a 
method of encoding audio information in a communication system may aim to reduce 
distortion induced by channel noise. Although the idea underlying such a method may be 
considered to reside in a mathematical method, the encoding method as a whole is not a 
mathematical method “as such”, and hence is not excluded from patentability by Article 
52(2)(a) and (3) EPC.150 Similarly, a method of encrypting/ decrypting or signing electronic 
communications may be regarded as a technical method, even if it is essentially based on a 
mathematical method.151  
Similar reasoning applies to medical diagnostic methods and methods of treatment by 
surgery or therapy which are excepted from patentabilty under Article 53(c) EPC, but only if 
practiced on the human body. Caselaw has interpreted this requirement very narrowly to allow 
the patentability of specific genetic diagnostic methods.152 Likewise it can be assumed that 
surgical methods conducted on bioprinted tissue and future bioprinted organs would prior to 
implantation not be considered to be practiced on the human body and would thus not fall 
under the surgical methods exception as interpreted by EPO case law.153 Moreover, Article 
53(c) EPC explicitly states that these exceptions shall not apply to products, in particular 
substances or compositions, for use in any of these methods.  
In sum, the formalistic European approach has, in contrast to the more substantive US 
approach in Prometheus and Alice, made patent-eligibility a rather low threshold. In Europe, 
the patent-eligibility standard has become primarily a question of drafting, where many mixed 
bioprinting claims and Big Data techniques could with clever drafting pass the patent 
eligibility threshold. Hence, many bioinformatics programs and increasingly sophisticated 
applications of these will remain patentable if fulfilling the other patentability requirements 
such as novelty, inventive step, industrial applicability and sufficient disclosure. 
 
4. Bioprinting and morality exclusions in patent law 
 
While the applications that bioprinting may provide are astonishing, many questions emerge, 
not just in relation to what applications are technically possible, but also whether they should 
actually be achieved. As with many other advances in science, such as nuclear power or 
biotechnology, issues arise with regard to the morality of new applications. Bioprinting may 
bring previously fictitious applications closer to reality. Furthermore, it was mooted that the 
ability to produce new organs may provide mankind with the key to extend the human 
lifespan154 or even enable immortality. These may be considerations that regulators and wider 
society may have to respond to.155 The ethical aspects created by advances in bioprinting 
revolve, inter alia, around issues surrounding the “cells” used for bioprinting, ownership of 
the bioprinted organ and the religious and socio-cultural acceptance of this technology.156 
Additionally, the future accessibility of this technology, in other words its cost, can be added 
                                                                                                                                                                                      
149 See T 0146/07 Prenatal diagnosis/ISIS (EPO 13 December 2011). 
150 Cf. Guidelines for Examination in the European Patent Office, Part G, Chapter II at 3.3, (November 2016), OJ 
EPO 2016, A76. 
151 T-1326/06 RSA Schlüsselpaarberechnung/GIESECKE & DEVRIENT (EPO 30 November 2010). See also T 
1227/05 Schaltkreissimulation I/Infineon Technologies (EPO 13 December 2006). 
152  Opinion G-1/04 (Diagnostic methods) (16 December 2005) OJ EPO 2006, 334 (“Opinion G-1/04”). See also 
T 0146/07 Prenatal diagnosis/ISIS, supra n. 149, where patent eligibility was not even an issue. 
153 G 0001/07 Treatment by surgery/MEDI-PHYSICS (EPO 15 February 2010). 
154 Varkey & Atala, supra n.14, 291. 
155 S. Vijayavenkataraman, W.F. Lu and J.Y.H. Fuh, 3D bioprinting – An Ethical, Legal and Social Aspects 
(ELSA) framework, 1-2 Bioprinting, 18 (2016). 
156 Sanjairaj Vijayavenkataraman, A Perspective on Bioprinting Ethics, 40(11) Artificial Organs 1033, 1034-1035 
(2016). 
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here. While bioprinting could provide individualised medicine with all its benefits, conversely 
it could mean that it may only be available for certain people that can afford it.157   
Aside from these more general moral questions, this section will focus on the narrower 
question that arises in the context of the patentability of inventions involving bioprinting. In 
this regard, the TRIPS Agreement permits WTO Member States to exclude inventions “within 
their territory of the commercial exploitation of which is necessary to protect ordre public or 
morality, including to protect human, animal or plant life or health or to avoid serious 
prejudice to the environment, provided that such exclusion is not made merely because the 
exploitation is prohibited by their law.”158 
 
 
4.1 Morality considerations under US law 
 
The United States has not included a broader and generally applicable morality provision 
within its patent law.159 Instead the “moral utility” doctrine was developed by case law and 
was applied to invalidate frivolous or scandalous patents, usually gambling machines and 
fraudulent articles.160 This doctrine provided a legal fiction that such inventions would not be 
“useful” according to the patent-eligibility provision of 35 U.S.C. § 101 of the US Patent 
Statute.161 But this doctrine stands in contrast to the US Supreme Court decision in Diamond 
v. Chakrabarty162 which declared that ‘anything under the sun that is made by man’ would 
generally be patentable. Additionally, the Courts of Appeal for the Federal Circuit have 
questioned the doctrine since section 101 would not mandate an assessment of morality.163  
Hence, questions surrounding morality do not normally constitute a significant bar as such to 
patenting in the United States. The patentability of stem cells is rather discussed within a 
technical debate over patent-eligibility and in the context of the so-called “natural 
phenomena” and “product of nature” doctrines. 164 As mentioned before, these debates have 
recently been invigorated by the Supreme Court decisions in Prometheus, Myriad, and Alice, 
but the focus appears to be on utilitarian considerations rather than on arguments based on 
morality or ordre public.  
However, one exception exists under US law, which potentially might have further 
implications for bioprinting: Section 33 of the America Invents Act165 states that 
“[n]otwithstanding any other provision of law, no patent may issue on a claim directed to or 
encompassing a human organism.” This provision aims to ban the patenting of human beings 
at any stage of development, including embryos, fetuses, human/non-human chimeras, and 
                                                          
157 Varkey & Atala, supra n.14, 287. 
158 Article 27(2) TRIPS. 
159 With the minor exception that HR 1249 (the America Invents Act) introduced an immediately effective ban on 
patents covering tax strategies and/or claims ‘directed to or encompassing’ human organisms. These will apply to 
all pending applications. Moreover, the USPTO had previously refused to grant patents on human chimera, cf. 
Ana Nordberg and Timo Minssen, A "ray of hope" for European stem cell patents or "out of the smog into the 
fog”? An analysis of recent European case law and how it compares to the US, 47 (2) International Review of 
Intellectual Property and Competition Law, 138, 169 (2016) [adding in FN. 182 “Until recently nuclear weapons 
were the only invention category completely excluded from patent eligibility (albeit not from a prize system). Yet 
this exclusion was not codified in the Patent Act, but in the Atomic Energy Act. 42 U.S.C. § 2181(a) (2000)”]. 
160 Joshua Whitehill, Patenting Human Embryonic Stem Cells: What is so Immoral? 34 (3) Brooklyn Journal of 
International Law, 1045, 1075-1075 (2009); Margo A. Bagley, Patent first, ask questions later: morality and 
biotechnology in patent law, 45 (2) William and Mary Law Review, 469, 489 (2003). 
161 Bagley, supra n. 160, 476. 
162 447 U.S. 303 (1980). 
163 Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364 (Fed. Cir. 1999). 
164 Nordberg & Minssen, supra n. 159, 171. 
165  Leahy-Smith America Invents Act, HR 1249. 
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clones. Under current case law this would normally not comprise human embryonic stem cells 
and organs. But some commentators, such as Ava Caffarini, note that the vague wording of 
section 33 and the lack of definitions for “directed to” and “human organism,” give courts 
wide latitude when construing section 33, which could in the future lead to a construction that 
would invalidate several biotechnology  inventions.166 This view is also shared by Jasper L. 
Tran who notes:  
 
Courts could potentially construe § 33(a) broadly to derail patent eligibility of many inventions, 
including bioprinting.[16]But until the legislature or courts interpret “directed to or encompassing a 
human organism,” the Patent Office can reject any bioprinting claim “directed to” or 
“encompassing” human under the broadest reasonable interpretation.[17] Patent prosecutors must 
carefully draft bioprinting claims to avoid falling into this pothole. One possible way is to couch 
bioprinted human living tissues as implants or medical devices to use in a human body. For 
example, U.S. Patent No. 8,394,141 claims an implant formed from “fibers of defatted, shredded, 
allogeneic human tissue” including a “tendon, fascia, ligament, or dermis” and a “growth factor” 
(to induce cell growth).167 
 
4.2. Morality considerations under European law 
 
Within the European context, however, Article 53(a) of the EPC explicitly excludes 
patent protection for any invention “the publication or exploitation of which is contrary to 
ordre public or morality.” National patent laws have also introduced similar bars to that of the 
EPC.168169Additionally, the then European Communities legislated within the field of 
biotechnological inventions. After many years of discussion, the European legislator adopted 
Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal 
protection of biotechnological inventions (Biotech Directive).170 The Directive provided 
specific rules on this issue with regard to biotechnological inventions. Article 6(a) of the 
Biotech Directive mirrors that of Article 53(a) of the EPC to a great degree.171 This provision 
reads: 
 
1. Inventions shall be considered unpatentable where their commercial exploitation would be contrary 
to ordre public or morality; however, exploitation shall not be deemed to be so contrary merely 
because it is prohibited by law or regulation. 
 
Article 6, section 2 of the Biotech Directive (see also Rule 28 of the Implementing 
Regulations of the EPC) provides an additional non-exhaustive list172 of specific case groups 
describing when inventions are deemed to be unpatentable in the context of subsection 1: 
 
                                                          
166   Ava Caffarini, Directed To or Encompassing a Human Organism: How Section 33 of the America Invents 
Act May Threaten the Future of Biotechnology, 12 J. Marshall Rev. Intell. Prop. L. 768 (2013). 
167  Tran, supra n. 116, 2. 
168 The Convention on the Unification of certain points of substantive law on patents for invention (Strasbourg 
Convention) from 1963, which served as a template for some of the substantive rules within the EPC, already 
provided a similar provision within its Article 2(a).  
169 E.g. Section 1(3)(a) UK Patents Act 1977; Section 2 (1) German Patents Act; Section 2 (1)(1) Austrian Patent 
Act. 
170 Directive on the legal protection of biotechnological inventions by the European Parliament & Council, pp. 
13–21 (30 July 1998), OJ L 213 (Biotech Directive). 
171 Åsa Hellstadius, A Comparative Analysis of the national implementation of the Directive’s morality clause, in: 
Aurora Plomer and Paul Torremans (eds.) Embryonic Stem Cell Patents  - European Law and Ethics (OUP 
2009), 120. For a more detailed and wider discussion of morality exclusions in patent law, see also Åsa 
Hellstadius, A Quest for Clarity: Reconstructing Standards for the Patent Law Morality Exclusion (Stockholm 
University 2015).  
172 Recital 38 Biotech Directive. 
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2.   On the basis of paragraph 1, the following, in particular, shall be considered unpatentable: 
(a) processes for cloning human beings; 
(b) processes for modifying the germ line genetic identity of human beings; 
(c) uses of human embryos for industrial or commercial purposes;  
(d) processes for modifying the genetic identity of animals which are likely to cause them suffering 
without any substantial medical benefit to man or animal, and also animals resulting from such 
processes. 
 
While questions surrounding morality and patentability did not arise for some time, 
advances in the field of biotechnology pushed these issues into the limelight.173 After adoption 
of the Directive, the Administrative Council of the EPO added Rules 23(b) to 23(e) (now rule 
26-34 EPC 2000) to the Implementing Regulations of the EPC.174 Hence, the discourse was 
mainly led within the EPO by its examining, opposition divisions as well as their BoA. But 
with the implementation of the Biotech Directive, the Court of Justice of the European Union 
(“CJEU”) also became a major forum in the debate, since it is the competent court to interpret 
EU legislation. Along with national laws and the emerging Unitary Patent System, this 
provides a diverse framework of different fora with different legal traditions which makes the 
debate on morality and patenting more complex. 
As mentioned, advances in the field of biotechnology have heavily influenced 
application of the morality exclusion. The case law on this exclusion has largely been 
generated by the implications of biotechnological inventions. Furthermore, the adoption of the 
Biotech Directive with its specific elaborations of what is deemed to be unpatentable in its 
Article 6(2) underline that the EU legislator found it necessary to clarify certain aspects of 
patenting in the field of biotechnology.175 While the patenting of bioprinting may pose similar 
challenges, especially with regard to use of human embryonic stem cells (hESC) in bioink, it 
is submitted that the new and distinct applications that bioprinting may offer in future, such as 
use of xenogenic cells or creation of enhanced organs, will require a new assessment as to 
their compatibility with ordre public and morality.  
For the purposes of this analysis, it is useful to differentiate the provisions governing 
immoral patents at the outset. The terms “ordre public” or “morality” of Article 53 EPC 
provide indeterminate terms which necessarily require interpretation. In contrast, the 
provisions on morality within the Biotech Directive, while only providing a non-exhaustive 
list, provide more or less clear case groups or examples when an invention is deemed to be 
immoral.176 Hence, these specific case groups are discussed initially as they may apply to 
applications of bioprinting. Where the leges speciales of these case groups do not apply, one 
can revert to the more general rules of Article 6(1) Biotech Directive/ Article 53(a) EPC.177 
Article 6(2)(a) of the Biotech Directive and Rule 28 (a) of the EPC’s Implementing 
Regulations declare processes for the cloning of human beings unpatentable. Recital 40 of the 
Directive mentions that “there is a consensus within the Community that interventions in the 
human germ line and the cloning of human beings offends against ordre public and morality” 
which is why the Directive would “exclude unequivocally” such processes from patentability. 
Hence, where bioprinters could be used to replicate human beings in the future using cloning 
                                                          
173 Lionel Bently and Brad Sherman, Intellectual Property Law, 515 (4th ed., Oxford University Press 2014). 
174 In 1999 the member states of the European Patent Organisation decided to implement the Directive by 
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175 Recital 38 Biotech Directive. 
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technology,178 a patent application containing such a process would fall within the ambit of 
the provision and be rejected. 
Tissue engineering is one application that can already be achieved through 
bioprinting.179 The technology allows for several cells to be used in bioink, including stem 
cells. The great medical potential that stem cells possess is based on their ability to develop 
into any cells of the body. It has been said that stem cells will have an important role to play in 
the development of bioprinting.180 The question of morality is focused on the use of hESC 
whereby the treatment often leads to the destruction of the embryo.181 Until alternative ways 
are found to create stem cells that have similar properties to hESC182, uses of these cells will 
remain “the most dominant ethical question” for bioprinting.183 
Article 6 (2)(c) of the Biotech Directive specifically considers such inventions 
unpatentable where they relate to “uses of human embryos for industrial or commercial 
purposes.” This provision was discussed in the Brüstle decision of the CJEU.184 The patent in 
suit concerned “isolated and purified neural precursor cells, processes for their production 
from embryonic stem cells and the use of neural precursor cells for the treatment of neural 
defects.”185 The stem cells within the process in question derived from blastocysts. The Court 
had, inter alia, to assess whether such blastocysts could be considered as embryos in the 
reading of the Directive.186 The Court affirmed this and found that the patent would violate 
Article 6 (2)(c) Biotech Directive since its technical teaching “requires the prior destruction of 
human embryos or their use as base material, whatever the stage at which that takes place and 
even if the description of the technical teaching claimed does not refer to the use of human 
embryos.”187 
The CJEU’s decision was criticised,188 inter alia, because of its autonomous 
interpretation of what would constitute an embryo.189 The Court’s interpretation would 
consequently mean that a patent of a bioprinting process for tissue engineering that would 
include the destruction of human embryonic stem cells or their use as a base material would 
not be patentable. The Brüstle decision, however, needs to be contrasted with the subsequent 
decision in ISCO.190 Here, the CJEU appeared to have narrowed its interpretation of Article 
6(2)(c) of the Biotech Directive. It held that non-fertilised ova would only be considered to be 
human embryos if found ‘‘capable of commencing the process of development of a human 
being just as an embryo created by fertilisation of an ovum can do.’’191 Some commentators 
therefore conclude that the CJEU aimed at correcting its verdict on human embryonic stem 
cells: “[T]he CJEU recognised that in Brüstle it had relied on incorrect scientific data 
concerning parthenotes, but it did so only indirectly, and fell short of actually acknowledging 
                                                          
178 Tran, supra n. 12, discusses this possibility at 153-154. 
179 See supra in Section 1 of this paper:  “Bioprinting: A brief scientific preface.”  
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190 C-364/13 International Stem Cell Corporation v. Comptroller General of Patents (ISCO), OJ C 65, 7 (18 
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that there had been a technical failure or that the CJEU was misdirected or had misunderstood 
the science at issue”.192 
Currently, there is no general prohibition to use hESC in processes for bioprinting. The 
ISCO decision clarified that the creation of hESC from blastocyst-like structures created by 
stimulation of unfertilised ova through parthogenesis is possible since they are not considered 
as human embryos.193 This means that patent protection for bioprinting processes is possible 
where the stem cells derive from such processes that avoid destroying fertilised ova.194 But the 
range of possible medical applications is limited with these permissible stem cells195 and 
developments surrounding induced pluripotent stem cells have not yet technically matured.196 
Other applications enabled through bioprinting may have to be assessed by the more 
general rules of Article 53 EPC/Article 6(1) Biotech Directive or its respective national 
counterparts. The obvious difficulty that surrounds the application of these provisions relates 
to defining what is immoral or what would be contrary to the ordre public. Since these 
provisions constitute hurdles to the grant of a patent, the additional question arises as to 
whether patent examiners are qualified to assess questions of morality. The Examining 
Guidelines of the EPO mention that inventions are deemed to be contrary to morality or ordre 
public where they are outrageous and provide a patent application for anti-personnel mines as 
an example for an abhorrent invention deemed to be immoral.197  
The Technical Board of Appeal (TBA) clarified that morality relates to the “belief that 
some behaviour is right and acceptable whereas other behaviour is wrong, this belief being 
founded on the totality of the accepted norms which are deeply rooted in a particular 
culture.”198   Importantly, the TBA added that “for the purposes of the EPC, the culture in 
question is the culture inherent in European society and civilisation.”199 However, the TBA 
discarded often referred-to bases for assessing morality such as economic or religious 
considerations as they would not represent a common standard in European Culture200 and 
questioned the usefulness of opinion polls.201 With regard to interpretation of Article 53(a) 
EPC, the TBA held that the provision would constitute an exception to the generally wide 
concept of patentability and should therefore be construed narrowly.202  
In the Onco Mouse cases that relate to a mouse that has been genetically modified to 
be susceptible of generating cancer, the EPO applied a utilitarian calculus. The TBA suggested 
that the question of patentability of such an invention would depend on “weighing up of the 
suffering of animals and possible risks to the environment on the one hand, and the 
invention’s usefulness to mankind on the other.”203 In applying this test, the Examining 
Division of the EPO concluded that a patent would not be rejected when its benefits would 
outweigh its negative impacts.204 In the second Onco Mouse case, the TBA held that the 
utilitarian balancing test could be applied as a general test for morality or ordre public 
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cases.205 In the bioprinting context, the question is then how this calculus would apply and 
which considerations would be weighed against each other. Bioprinting applications which are 
not aimed at curing diseases, but in creating new improved characteristics of organs for 
humans may become an issue in the future. It has been said that such applications would be 
possible and sought after by individuals wishing to acquire enhanced characteristics and 
abilities, in particular athletes.206 The question would very much lie in how such artificial 
improvements would be seen by the wider society and will pose an area of discussion for the 
ethics of bioprinting. An analogy from doping could be applied in this context. But the 
question may need to be assessed whether artificial enhancement of human beings through 
bioprinting is a desirable achievement that outweighs the potential negative aspects. 
Aside from the already discussed use of stem cells, other cell material and tissue taken 
from human beings is used in bioprinting. The aforementioned Relaxin case207 before the EPO 
shed some additional light on the question whether patents on human DNA are against 
morality or ordre public. With regard to the morality clause the opponent argued, inter alia, 
that the patent would violate Article 53(a) EPC “insofar as it relates to a DNA fragment 
encoding human H2-relaxin and its precursors.”208  In this regard the opposition was founded 
on three points: First, that the human right of self-determination would be infringed because 
the patenting of human genes would constitute a form of slavery. This was because it would 
“involve [] the dismemberment of women and their piecemeal sale to commercial enterprises 
throughout the world.”209  Additionally, the argument was raised that it was offensive against 
human dignity to profit from pregnancy and that it as intrinsically offensive to patent human 
life. The Opposition division, however, found that these claims were not founded. It held that 
the samples taken from the women were provided with consent. Additionally, it emphasised 
the nature of patents as a negative right to exclude third parties from using the patent. It does 
not provide rights over human beings. It also rejected the claim that patents on life were 
immoral as the patent in suit would relate to “a chemical substance which carries genetic 
information.”210  
This case provides important ramifications for patents involving bioprinting, since it 
implies that the use of human tissue as such is not immoral or against ordre public. This is 
relevant where cells are taken through a biopsy from a patient or other donors211 and used for 
bioink in a bioprinting process. Based on the reasoning of the Relaxin decision212, the use of 
cells in the teaching of the patent is not considered to be immoral where their use is based on 
the informed consent of the respective patient or donors.213  Then no violation of Article 53(a)/ 
Article 6(1) Biotech Directive would be found.  
An issue that could constitute a violation of the morality exclusion may be the use of 
xenogeneic cells in bioprinting. This could, for instance, occur where enhanced tissue is being 
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produced by mixing human cells with those of animals.214 Article 6 (2) (b) of the Biotech 
Directive only sanctions such “processes to produce chimeras from germ cells or totipotent 
cells of humans and animals.”215 The idea of creating such enhanced organs by using animal 
cells may be found abhorrent by many and would therefore constitute an obstacle to patenting. 
It can also be doubted that such applications may be subject to a positive finding on the 
utilitarian calculus that the EPO applies.  
 
 
5. Conclusions  
 
This contribution highlighted the current state of the art and future applications of bioprinting 
technologies, which are already attracting increasing patent activity. Most bioprinting 
technologies and printing machines, as well as synthetically produced biological material and 
technical processes would often meet basic patent eligibility criteria in both Europe and in the 
US. However, recent US case law developments have severely limited the patentability of 
naturally occurring biological material and natural phenomena and correlations. In contrast, 
European patent law still regards isolated biological material, as well as technical methods 
based on natural phenomena that are not claimed as such, as in principle patent-eligible. On 
the other hand, the scope of protection granted in Europe might be rather limited in Europe 
and moral concerns might pose a potentially higher bar to patentability for some applications 
than in the US. In Europe, patent challenges may be based on morality clauses enshrined in 
the EPC and national patent laws to bar particular patent applications covering bioprinting 
technology. In the US these concerns are more limited, but a wider interpretation of the AIA’s 
section 33 may pose a bar to several bioprinting applications. As elaborated, the application of 
the morality exclusions is a difficult task that patent offices need to achieve. Some clarity has 
been provided with regard to use of human embryonic stem cells but the further bioprinting 
technologies develop the more morality issues may arise. For the sake of promoting this new 
field of technology, we believe that only utterly abhorrent patent applications should be barred 
on the basis of morality. 
Notwithstanding the ongoing debates on the patentability of biotechnological 
innovations, the market leaders in bioprinting will certainly continue to press the boundaries 
of what is possible in bioprinting and will continue to seek patent protection for their 
innovations and scientific advances. As 3D bioprinted products become more sophisticated 
and approach widespread use in clinics and hospitals, it can further be assumed that the actors 
with the biggest and most relevant patent portfolios will team up to develop patient-specific 
products.216 In recent years, fascinating advances have e.g. been made with liver and kidney 
cells, which may begin clinical testing in the near future.217 For products that will interact or 
reside within the human body, FDA and EMA testing and approval is crucial for many 
bioprinting companies to profit.218 The special expertise that is required to gain FDA or EMA 
approval will probably motivate more companies to enter into partnerships and to purchase 
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patents and acquire companies.219 The bioprinting IP power structure is thus in a state of flux 
and it can be expected that we will see many changes and consolidations in the sector.220 
While patents will remain important in stimulating scientific progress in this area, the 
wide and diverse fields of patent activity in the field might also create problems. The great 
variety of patents and patent applications where few market-leaders with enormous patent 
portfolios, such as Organovo Inc., hold many overlapping patents covering key technologies, 
could lead to patent thickets and other potential anticommons scenarios.221 However, before 
the first fully functional bioprinted organs and more complex tissues can be made and 
approved by regulatory authorities, it is highly likely that many basic patents will have 
expired. Moreover, many countries have codified various exceptions to patent infringement, 
such as research and experimental use exemptions. Unfortunately, these exemptions have a 
rather unclear scope of application. We therefore believe that an international clarification and 
more harmonized approaches with regard to such types of exemptions would be very helpful 
for effectively stimulating research in bioprinting, and in many other cutting-edge areas of life 
science 
Among the technological trends that will have to be observed is the use of Big Data in 
bioinformatics, since it will enable the field's next wave of breakthroughs. So far, most 
bioprinting technologies have lacked biologically sophisticated software and other 
bioinformatics tools.222 However, rapid advances in systems biology and synthetic biology in 
combination with the evolution of Big Data applications are now providing increasingly 
powerful tools, and it is clear that the interface between Big Data, competition law, 
standardization and a broad plethora of applicable IPRs, needs to be studied very carefully 
within the bioprinting area.223 
Last but not least, it remains important to recall that any IP and competition law-
related issues are dwarfed by the enormous regulatory and public policy challenges that are 
ignited by bioprinting on a more general level. As personal 3 D printers become more 
powerful and common, as independent service providers open their doors and grant access to 
increasingly sophisticated printers, and as industrial or private customers realize that they can 
produce replacement parts and other potentially harmful products, the democratization of 
manufacturing will increase and move away from control.224 It is clear that this will have 
broader implications in many areas of currently applicable laws, such as criminal law, 
regulatory law, environmental law, constitutional law and for safety regulations, which are 
likely to become increasingly irrelevant or outdated.225 In the bioprinting area with its strong 
impact on sensitive goods and values such as human rights, health, integrity and dignity, this 
is a particularly challenging development. It is thus clear that 3D printing, and bioprinting in 
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particular, is an enormous game-changer that needs to be monitored very carefully and might 
require forceful and concerted interventions. Only then will it be possible to meet public 
policy objectives and to find a reasonable balance between prevention of harmful misuses and 
realization of the enormous benefits that will certainly result from this fascinating technology 
 
 
 
 
